Allergy Thera. Share News (AGY)

Allergy Therapeutics Completes Patient Enrolment For Birch Study

Allergy Therapeutics raises £12m to develop peanut and dust mite treatments

(ShareCast News) - Shares in Allergy Therapeutics fell as, despite a strong trading update, the company launched a £12m discounted fundraising to speed development of treatments for peanut allergy and house dust mites allergies. The AIM-listed company completes the institutional placing by mid-after

UPDATE: Allergy Therapeutics Raises GBP11.5 Million To Fund Growth (ALLISS)

Allergy Therapeutics To Raise GBP12 Million To Fund Growth (ALLISS)

AGM, EGM Calendar - Week Ahead

Allergy Therapeutics To Present Adjuvant Data At Spain Conference

BROKER RATINGS SUMMARY: Citi Cuts AB Foods As UBS Raises Smiths Group

Allergy Therapeutics Says Outlook "Very Positive" As Profit Falls

Earnings, Trading Statements Calendar - Week Ahead

Allergy Therapeutics Enrols First Patient For Birch Drug Study

Allergy Therapeutics Says Paper Published In World Allergy Journal

Allergy Technologies' chief executive buys 50,000 shares

(ShareCast News) - The chief executive of Allergy Therapeutics bought new shares in the company few days after releasing a positive trading update. Manuel Llobet purchased 50,000 shares for an individual price of 24.45p, spending a total of £12,225. After the transaction, Llobet holds 3.175m shares

DIRECTOR DEALINGS SUMMARY: New MySale Chairman Buys 60,000 Shares

DIRECTOR DEALINGS: Allergy Therapeutics CEO Buys 50,000 Shares

Allergy Therapeutics Expects Revenue Growth Despite Euro Weakness